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Abstract
Purpose of Review The purpose of this study is to review
the evidence that lower risk groups who could safely be
screened less frequently for sight-threatening diabetic reti-
nopathy (DR) than annually.
Recent Findings Data have demonstrated that people with
no DR in either eye are at a low risk of progression to
sight-threatening DR over a 2-year period (event rate 4.8
per 1000 person years), irrespective of whether the screen-
ing method is one-field non-mydriatic or two-field mydri-
atic digital photography. Low risk has been defined as no
retinopathy on two consecutive screening episodes or no
retinopathy on one screening episode combined with risk
factor data.
Summary The risk of an extension to 2 years is less than
5 per 1000 person years in a population with a national
screening programme, and the general standard of diabe-
tes care is relatively good, whether low risk is defined as
no retinopathy on two consecutive screening episodes or
no retinopathy on one screening episode combined with
other risk factor data. The definition used in different
populations is likely to depend on the availability of
data.
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Introduction
In the UK, the Office for National Statistics publishes an
interesting graph of life expectancy over the last two cen-
turies [1], and this has demonstrated that life expectancy
has doubled from 40.2 years for men and 42.2 years for
women to 79 and 82.8, respectively. Life expectancy has
risen around the world and, although there are still differ-
ences between countries, even countries with lower levels
of life expectancy have also almost doubled their life ex-
pectancy during the last two centuries [2].
The increased life expectancy has led to a change in the
nature of the diseases we are treating. There are many more
patients in older age groups with chronic diseases such as
diabetes and cancer. There is an epidemic of diabetes [3, 4]
around the world, which has led to an epidemic of diabetic
retinopathy (DR) [5].
Various DR screening programmes have been set up
around the world. Population-based screening programmes
tend to be more successful in countries with state-run
nationalised health systems because of the infrastructure
and finance that is in place to support these programmes.
Early pioneering work on screening for DR was conducted
in Iceland [6, 7] and Sweden [8], and this was later intro-
duced in the UK [9–11], in other European countries
[12–14] and in Singapore [15]. In the USA and Australia,
screening programmes have tended to be in indigenous
populations [16–18], linked to diabetes clinics [19], in
Veterans Administration Healthcare systems [20], or in re-
search programmes [21]. There has also been interest in the
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development of screening programmes for DR in India
[22], China [23], and South America [24]. In England,
the epidemic of diabetes has proved to be a problem for
the screening programme because of the increasing num-
bers each year. When screening was introduced in England
in 2003, it was believed that there were approximately 1.4
million people with diabetes who needed to be screened,
and this number has risen to 2.6 million.
The annual report [25] of National Health Service
(NHS) screening programmes in England 2015–2016 re-
ported that there were 2.59 million people with diabetes
offered screening with 2.14 million being screened (an up-
take of 82.8%) with urgent referrals for proliferative DR of
7593 and routine referrals of 52,597. Routine referrals are
either for moderate to severe non-proliferative DR or signs
of maculopathy using two-dimensional markers. The rate
of referable retinopathy per 100,000 screened was 2807. In
the same period (2015–2016), the largest number of new reg-
istrations of people with diabetes was recorded—326,587.
In the first and second rounds of screening, the referable
retinopathy rate was considerably higher than in subsequent
rounds of screening. For example, in the Gloucestershire
screening programme, the referable rate of retinopathy was
11.2% in the first round of screening in 1998–2000 [26]. In
addition, in populations who are screened for diabetes
[27–29], which is becoming more common, the rate of any
DR is much lower (7.6, 6.8, and 9%) than the prevalence in a
known population of people with diabetes. In a review of 35
studies by Yau [30], the overall prevalence of any DR was
34.6% (95% confidence interval (CI) 34.5–34.8), 6.96%
(6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for dia-
betic macular oedema, and 10.2% (10.1–10.3) for vision-
threatening DR.
Purpose of This Review
These factors have all led to the need to re-evaluate the need
for annual screening for the whole population of people with
diabetes and ascertain whether there are lower risk groups
who could safely be seen less frequently.
Methods
The author has conducted an on-going literature review since
March 2000 utilising Zetoc [31] which provides access to over
30,000 journals and more than 52 million article citations and
conference papers through the British Library’s electronic ta-
ble of contents.
The following subject title keywords are used:
‘retinopathy’, ‘digital’ and ‘imaging’ and ‘eye’, ‘digital’ and
‘imaging’ and ‘ophthalm’, ‘digital’ and ‘imaging’ and
‘diabet’, ‘laser’ and ‘eye’, ‘laser’ and ‘ophthalm’, ‘laser’ and
‘diabet’, ‘visual’ and ‘acuity’, ‘visual’ and ‘impairment’,
‘blindness’ and ‘diabet’, ‘diabetic’ and ‘screening’, ‘uptake’
and ‘screening’ and ‘diabet’ in title, ‘attendance’ and ‘screen-
ing’ and ‘diabet’, and ‘vitrectomy’ and ‘diabet’, and ‘diabet’
and ‘screening’ and ‘interval’ in title.
The contents’ page lists of 27 journals, considered to be
those most likely to publish articles relevant to this topic, are
also reviewed each month. Articles of interest identified with
this search strategy were sourced from the local NHS Trust
library or online from electronic journal resources.
Results
I have identified 26 articles relevant to the purpose of this
review. Most of these articles come from established national
or regional screening programmes with good population cov-
erage and a relatively high standard of diabetes care, and so
these findings may not be applicable to areas where the stan-
dard of diabetes care is not as high or where screening is not
established.
A. Evaluation of real-world screening programmes
1. In 2003, Younis [32, 33] reported the incidence of sight-
threatening retinopathy in patients with both type 1 and
type 2 diabetes in the Liverpool Diabetic Eye Study.In
type 1 diabetes [32], 501 patients underwent 2742 screen
events. Cumulative incidence of sight-threatening DR in
305 patients without baseline retinopathy was 0.3% (95%
CI 0.0–0.9) at 1 year, rising to 3.9% (1.4–5.4) at 5 years.
The study concluded that screening at 2–3-year intervals,
rather than annually, for patients without retinopathy in
type 1 diabetes is feasible because of the low risk of pro-
gression to sight-threatening DR.
In type 2 diabetes [33], 4770 patients underwent 20,570
screening events. Yearly incidence of sight-threatening DR
in 3743 patients without retinopathy at baseline was 0.3%
(95% CI 0.1–0.5) in the first year, rising to 1.8% (1.2–2.5)
in the fifth year; cumulative incidence at 5 years was 3.9%
(2.8–5.0). The study concluded that a 3-year screening inter-
val could be safely adopted for patients with no retinopathy.
2. In 2007, Olafsdottir [34] reported that 296 patients with
diabetes in Iceland who had no DR in 1994/1995 were
followed with biennial eye examinations until they devel-
oped any retinopathy when they were reviewed with an-
nual eye examinations. Over the 10-year period, 172 did
not develop any retinopathy, 96 developed mild non-
proliferative DR, 6 developed clinically significant mac-
ular oedema, 23 developed moderate to severe non-
proliferative DR, and 4 developed proliferative DR. All
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those who developed macular edema or proliferative DR
had already been diagnosed with mild non-proliferative
DR and entered annual screening before progressing to
this level at a subsequent screening event. They concluded
that biennials screening for those without retinopathy was
safe.
3. In 2009, Misra et al. [35] analysed the results of 63,622
screening episodes among 20,788 people, 16,094 (25%)
identified any retinopathy, 3136 (4.9%) identified re-
ferable retinopathy, and 384 (0.60%) identified sight-
threatening DR (defined as proliferative DR or treat-
able maculopathy). They found that, compared with
screening intervals of 12–18 months, screening inter-
vals of 19–24 months were not associated with an
increased risk of referable retinopathy [adjusted odds
ratio 0.93, 94% CI 0.82–1.05].
4. In 2009, Soto-Pedre [36] reported on 286 patients from
northern Spain with diabetes free of DR and 144 patients
with mild non-proliferative DR at baseline who had been
screened with one-field non-mydriatic photography. For
the 286 patients free of DR, the probability of remaining
free of sight-threatening DR was 97% (95% confidence
interval [CI] 94–99%) at the end of the fourth year.
5. In 2011, Agardh [37] reported the experience of adopting
3-year screening intervals for sight-threatening retinal
vascular lesions in subjects with type 2 diabetes without
retinopathy in Sweden. 1691 subjects with type 2 diabetes
and no detectable retinopathy in two 50° red-free fundus
photographs were scheduled for follow-up with photog-
raphy 3 years later. Age at diabetes diagnosis was
60 ± 12 years, and known duration of diabetes was
6 ± 6 years. Treatment consisted of diet only (26%), oral
agents (54%), and oral agents and/or insulin (20%).
Glycated hemoglobin (HbA1c) was 6.4 ± 1.5%. Of the
1322 subjects available for follow-up, 73% were still
without retinopathy after 3 years, and 28% had developed
mild or moderate retinopathy, but none developed severe
non-proliferative or proliferative retinopathy. Macular
edema requiring laser coagulation occurred in only one
eye. The study concluded that 3-year retinal screening
intervals can be recommended in subjects with type 2
diabetes and no retinopathy.
6. In 2013, Scanlon [38] reported that the risk of progression
of DR is significantly higher for those with background
DR in both eyes than those with background retinopathy
in only one or in neither eye. Prior to these low-risk
groups were generally regarded to be those people with
no DR in either eye.
7. In 2013, Porta [39] published the clinical characteristics
influencing screening intervals for DR. The cumulative
incidence, time of development, and relative risk of de-
veloping referable retinopathy over 6 years following a
negative screening for DR were calculated in 4320
patients, stratified according to age at onset of diabetes
(<30 or ≥30 years), being on insulin treatment at the time
of screening and known duration of diabetes (<10 or
≥10 years). The study concluded that screening can be
repeated safely at 2-year intervals in any patient without
retinopathy.
8. In 2015, Leese [40•] reported results from a Four Nations
working group which combined data from screening
programmes in England, Scotland, Wales, and Northern
Ireland. This was an observational study based on retinal
grading results between 2005 and 2012. In total, 354,549
patients were observed for up to 4 years during which
16,196 patients progressed to referable retinopathy. Of
patients with no retinopathy in either eye for two succes-
sive screening episodes at least 12 months apart, the con-
ditions of between 0.3% (95% CI 0.3–0.8%) and 1.3%
(1.0–1.6%) of patients progressed to referable retinopathy,
and rates of treatable eye disease were <0.3% at 2 years.
The corresponding progression rates for patients with bi-
lateral background retinopathy in successive screening
episodes were 13–29% and up to 4%, respectively, in
the different programmes.
9. In 2016, Hughes [41] recommended that the optimum
screening intervals should be determined from time to
active laser treatment. This is a cohort study of ophthal-
mologic outcomes in unselected diabetic patients attend-
ing a community screening programme in 2001/2002. At
screening, 2493 had no retinopathy; 424 had mostly mi-
nor degrees of non-proliferative retinopathy. Survival
analysis showed that very few of the no retinopathy at
screening group required laser therapy in the early years
compared with the non-proliferative retinopathy group
(p < 0.001). The study suggested that, based on require-
ment for laser therapy, the screening interval for diabetic
patients with no retinopathy can be extended to 2 to
3 years.
B. Modelling studies of the natural history of DR
1. In 2011, Aspelund [42] reported on the development
of a mathematical algorithm based on epidemiological
data on risk factors for DR. Through a website, www.
risk.is, the algorithm receives clinical data, including
type and duration of diabetes, HbA1c or mean blood
glucose, blood pressure, and the presence and grade
of retinopathy. These data are used to calculate risk
for sight-threatening retinopathy for an individual’s
worse eye over time. The database for DR at the
Department of Ophthalmology, Aarhus University
Hospital, Denmark, was used to empirically test the
efficacy of the algorithm. The algorithm recommends
screening intervals ranging from 6 to 60 months with
a mean of 29 months. This is 59% fewer visits than
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with fixed annual screening. This amounts to 41 annual
visits per 100 patients.
2. In 2012, Mehlsen [43], from the same group of re-
searchers, reported on the development of a model using
multiple logistic regressions, with previously defined in-
dividual risk factors, for individualised determination of
the screening interval in DR. The model was tested on
1372 patients screened during year 2000.
3. In 2012, Chalk [44] reported on the development of a
simulation model to predict the likely impact of screening
patients with type 2 diabetes, who have not been diag-
nosed with DR, every 2 years rather than annually. The
model was populated with data obtained from the annual
retinopathy screening in Devon, UK for a population of
approximately 20,000 people with diabetes and generated
comparative 15-year forecasts to assess the differences
between the current and proposed screening policies.
The simulation model predicted that implementing a 2-
year screening interval for patients with type 2 diabetes
without evidence of DR does not increase their risk of
vision loss, and this policy could reduce screening costs
by ~25%.
4. In 2013, Stratton [45••] described a risk stratification for
time to development of sight-threatening DR which in-
cluded results from two consecutive screening episodes.
5. In 2013, Looker [46] described the predicted impact of
extending the screening interval for DR: the Scottish
Diabetic Retinopathy Screening programme The lowest
probability for transitioning to referable background or
proliferative retinopathy was among people with two con-
secutive screens showing no visible retinopathy, where
the probability was <0.3% for type 1 and <0.2% for type
2 diabetes at 2 years. The study concluded that transition
rates to referable diabetic eye disease were lowest among
people with type 2 diabetes and two consecutive screens
showing no visible retinopathy. If such people had been
offered two yearly screening, the Drag Reduction System
(DRS) would have needed to screen 40% fewer people in
2009.
6. In 2014, Day [47] reported the sensitivity of DR-associated
vision loss to screening interval in an agent-based/discrete
event simulation model to examine the effect of changes to
screening interval on the incidence of vision loss in a sim-
ulated cohort of veterans with DR. DR-associated vision
loss increased as the screening interval was extended from
1 to 5 years (p < 0.0001). This increase was concentrated in
the third year of the screening interval (p < 0.01). There
was no increase in vision loss associated with increasing
the screening interval from 1 to 2 years (p = 0.98).
7. In 2016, Lund [48] reported a study to validate a mathe-
matical algorithm [42] that calculates the risk of DR pro-
gression in a diabetic population with the UK staging
(R0–3; M1) of DR. A cohort of 9690 individuals with
diabetes in England was followed for 2 years. The algo-
rithms calculated the individual risk for development of
pre-proliferative retinopathy (R2), active proliferative ret-
inopathy (R3A), and diabetic maculopathy (M1) based on
clinical data. The algorithm predicts the occurrence of the
given DR stages with area under the curve = 80% for
patients with type 2 diabetes (CI 0.78 to 0.81). Of the
cohort, 64% is at less than 5% risk of progression to R2,
R3A, or M1 within 2 years. By applying a 2-year ceiling
to the screening interval, patients with type 2 diabetes are
screened on average every 20 months, which is a 40%
reduction in frequency compared with annual screening.
C. Cost-effectiveness studies
1. In 2000, Vijan [49] examined the marginal cost-
effectiveness of various screening intervals for eye dis-
ease in patients with type 2 diabetes, stratified by age
and level of glycaemic control using a Markov cost-
effectiveness model. The study concluded that annual ret-
inal screening for all patients with type 2 diabetes without
previously detected retinopathy may not be warranted on
the basis of cost-effectiveness, and tailoring recommen-
dations to individual circumstances may be preferable.
Patients’ medical risk factors such as poor control were
found to have a substantially higher risk and extending
intervals without regard for medical risk factors may not
be warranted in all settings.
2. In 2015, Scanlon [50••] reported on the development of a
cost-effectiveness model for optimisation of the screening
interval in DR screening (funded by theHTA programme).
Risk factors were identified in Gloucestershire, UK using
survival modelling. Two personalised risk stratification
models were employed: two screening episodes (SEs)
(low, medium, or high risk) or one SE with clinical infor-
mation (low, medium-low, medium-high, or high risk).
The risk factor models were validated in other populations
in Nottinghamshire, South London, and East Anglia (all
UK). Data were obtained in Gloucestershire from 12,790
people with diabetes with known risk factors to derive the
risk estimation models, from 15,877 people to inform the
uptake of screening and from 17,043 people to inform the
healthcare resource-usage costs. Two stratification models
were developed: one using only results from previous
screening events and one using previous screening and
some commonly available GP data. Both models were
capable of differentiating groups at low and high risk of
development of sight-threatening DR. In this study,
the people with no DR in either eye were found to be at
the low risk of progression to sight-threatening DR over a
2-year period (event rate 4.8 per 1000 person years). Using
either risk stratification models, screening patients at low
risk every 5 years was the most cost-effective option, with
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a probability of 99–100% at a pound 30,000 per quality-
adjusted life-year threshold. For the medium-risk groups,
screening every 3 years had a probability of 43–48%,
while screening high-risk groups every 2 years was cost-
effective with a probability of 55–59%.
D. Commentaries
1. A commentary in 2003 by Professor Ron Klein [51] on
the recommendations from the Younis studies [32, 33]
made the following points:
a) Long intervals between follow-up visits may lead to dif-
ficulties inmaintaining contact with patients andmay give
patients the impression that vision loss is unlikely and
therefore not a concern.
b) That it might be better to have a conservative guideline of
yearly examinations with deviations based on evaluation
of risk (glycemic and blood pressure control) rather than
having a uniformly long interval.
c) The ability to generalise the observations of the Liverpool
study to other screening situations will depend on the
comparability of the population of people with diabetes
being screened to those in the Liverpool study and the
sensitivity of the approaches used to detect sight-
threatening DR and other ocular conditions.
2. In 2013, Leese [52] wrote a commentary exploring the
evidence for moving towards a biennial retinal screening
programme for patients with type 2 diabetes and diabetes
duration of less than 10 years. He also explained that a
UK-Four Nations group was critically looking at the evi-
dence for any such changes.
E. Studies of patient behavior or opinions of extending the
screening interval
In 2012, Yeo conducted two studies [53, 54]:
a) The first [53] was based on 1550 questionnaires distrib-
uted at DR clinics in Wales, with 600 complete responses
analysed. Eighty-five percent (n = 507) felt that they
should have their eyes screened every year. However,
65% (n = 390) of respondents would accept screening at
2- or 3-year intervals if medical evidence showed that it
was safe.
b) The second [54] was based on a response rate of 86.4%
from the 198 questionnaires administered at clinics,
which included a discrete choice experiment contained
eight pairwise choices in which screening provision was
described by five attributes: frequency of screening, travel
time, results time, ability of screening to detect other
changes, and explanation of results. Data were analysed
using logistic regression techniques. Respondents valued
four out of the five attributes [ability of screening to detect
other changes (P < 0.001), explanation of results
(P = 0.02), frequency of screening (P < 0.001), and travel
time (P = 0.007)]. Results time was not significant
(P = 0.1). The study concluded that respondents were
willing to accept a longer screening interval, as long as
preferences for other attributes of service provision (abil-
ity of screening to detect other changes, explanation of
results and travel time) were made available.
F. Review articles on screening intervals
1. In 2013, Echouffo-Tcheugui [55] published a systematic
review of screening intervals for DR and incidence of vi-
sual loss and included studies from PubMed and EMBASE
databases which were searched until December 2012.
Analysis of 15 studies showed that the aggregated evi-
dence from both the natural history and cost-effectiveness
models favors a screening interval > 1 year, but ≤ 2 years.
Such an interval would be appropriate, safe, and cost-
effective for people with no DR at diagnosis, while screen-
ing intervals ≤ 1 year would be preferable for people with
pre-existing DR. A 2-year screening interval for people
with no sight-threatening DR at diagnosis may be
safely adopted. For patients with pre-existing DR, a shorter
interval ≤ 1 year is warranted.
2. In 2016, Taylor-Phillips [56] conducted a systematic re-
view to determine whether it was safe to recommend that
the DR screening interval in the UK could be extended to
beyond 1 year. Electronic searches were performed on 1
October 2013, and hence, no studies after this date would
have been included. The study concluded that there was
insufficient evidence at that time to recommend a move to
extend the screening interval beyond 1 year.
3. In 2016, the UK National Screening Committee reviewed
[57] the evidence available. They recommended a change
from 1- to 2-year screening intervals for people at a low
risk of sight loss. The definition of low risk is two succes-
sive diabetic eye screening appointments with photo-
graphic grading of no DR. They recommended that the
current annual screening interval should remain for
all those with mild retinopathy detected in either eye.
They provided four appendices as evidence, which in-
cluded work by the groups that had previously published
[40•, 56]. They also provided a supplementary literature
review on ‘Does a change in screening interval lead to a
subsequent change in uptake?’ This review was unable to
find sufficient evidence to support the notion that a
change in screening interval would result in a change in
uptake of a screening programme. There was also an as-
sessment by UK Department of Health Economists that is
available on the website, using a cost-utility approach,
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whether it is cost-effective to change screening intervals,
within the NSC diabetic eye screening programme, ac-
cording to patient risk, using pre-publication results from
Health Economists at Oxford University who had worked
on the HTA project—Scanlon [50••].
Conclusions
The data from real-world screening programmes has demon-
strated that people with diabetes who have no DR in either
eye are at the low risk of progression to referable or sight-
threatening DR over a 2-year period (event rate 4.8 per 1000
person years). Low event rates appear to be irrespective of
whether the diagnosis of no DR is based on one-field non-
mydriatic photography as is used in the protocol in Scotland
[46] or northern Spain [36] or whether it is based on 2-field
mydriatic digital photography as is used in other UK countries
[32, 33, 35] and Sweden [37]. Data was combined between
these methods in the Four Nations Study [40•].
It is important to recognise, as pointed out by Professor
Klein in his 2003 article [51] that the generalizability of these
observations to other screening situations will depend on the
comparability of the population of people with diabetes being
screened and the sensitivity of the approaches used to detect
sight-threatening DR and other ocular conditions.
Cost-effectiveness studies [49, 50••] have suggested that
annual screening for all people with diabetes may no longer
be cost-effective.
There have been suggestions that the screening interval
should be lengthened to 2 years for ‘low risk groups’ which
has been variably defined by the following:
1. Two screening episodes with individualised risk factor
data
2. Two screening episodes with no retinopathy
3. One screening episode with individualised risk factor data
The only study that compared area under the curve of the
receiver operator curves for these three groups was the Health
Technology Assessment study by Scanlon [50••] which found
the following:
1. Two screening episodes with individualised risk factor
data—AUC 0.786 (95% CI 0.759 to 0.813)
2. Two screening episodes with no retinopathy—AUC
0.759 (95% CI 0.732–0.788)
3. One screening episode with individualised risk factor da-
ta—AUC 0.774 (95% CI 0.748–0.800)
In order to add in the risk factor data to screening data, there
needs to be links available to this extra data that are not readily
available to many population-based screening programmes.
Hence, the UK National Screening Committee has recom-
mended a change from 1- to 2-year screening intervals for
people who have two successive diabetic eye screening ap-
pointments with photographic grading of no DR.
There is a large gap in knowledge and research on how this
will affect individual patient behaviors and attendance for
screening programmes. Work by Yeo [53, 54] has suggested
that respondents would accept screening at 2- or 3-year inter-
vals if medical evidence showed that it was safe and as long as
preferences for other attributes of service provision (ability of
screening to detect other changes, explanation of results and
travel time) were made available. However, there is no current
evidence of patient’s behavior in these circumstances. There is
an on-going concern that if patients are told that they are at the
low risk of progression that:
1. They may make less effort in the control of their diabetes
and hence put themselves at a greater risk.
2. They may be less likely to attend in the future.
A currently funded project in Liverpool, UK [58] is study-
ing the introduction of personalised screening intervals and
may help to answer some of these questions in similar
populations.
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